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bstract
ackground: Cytomegalovirus infection in renal transplant recipients is a major clinical problem, with both short and long term sequelae.
nfection can occur as a result of reactivation of latent virus or new infection from donor tissues. The impact of donor and recipient serostatus
n viremia is well recognised, with seronegative recipients at greatest risk after transplantation of an organ from a seropositive donor. However,
he impact of grafting such organs into seropositive recipients is less clear.
bjectives: To assess the impact of recipient serostatus on the risk of CMV antigenemia in a large renal transplant cohort.
tudy design: We prospectively quantified CMV antigenemia over time in a cohort of 486 recipients. We analysed the antigenemia status
ccording to donor and recipient serostatus.
esults: Antigenemia was most common in seronegative recipients of organs from seropositive donors (D+/R−). Nevertheless, we observed
hat even in CMV seropositive recipients, the impact of donor serostatus on CMV antigenemia is still substantial (p = 0.006; OR = 2.2).
onclusions: In this large study, donor serostatus clearly plays a significant role in determining CMV risk, even in seropositive recipients.
2007 Elsevier B.V.
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. Introduction
Cytomegalovirus (CMV) is a significant problem in the
mmunosuppressed. In particular, renal transplant patients are
t high risk of disease in the early post-transplant period.
ong term survival of the graft may also be influenced by
nfection/reactivation (Schnitzler et al., 2003).
CMV may cause disease upon primary infection. Seroneg-
tive recipients are therefore at high risk, especially if the
onor organ is from a seropositive individual (Brayman et
l., 1988; Gjertson, 1992, 2003; Hirata et al., 1996; Ricart
t al., 2005; Schnitzler et al., 2003; Warrell et al., 1980).
lternatively CMV may cause disease upon reactivation inmmunosuppressed individuals, where immune surveillance
s depressed as a result of disease or drug therapy (Rao et al.,
000; Warrell et al., 1980).
∗ Corresponding author. Tel.: +44 1865 281885; fax: +44 1865 281236.
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Open access under CC BY license. To analyse the role of pre-existing immunity in con-
rol of CMV post-transplant, we assessed antigenemia in
large cohort of renal transplant patients who had been
arefully prospectively followed. The antigenemia assay is
robust quantitative measure of CMV reactivation which
as been used in many previous studies (Pancholi et al.,
004). We analysed four patient groups, donor seropositive,
ecipient seropositive (D+R+), donor seronegative recipi-
nt seronegative (D−R−), and the mismatched D+R− and
−R+ groups. Specifically we analysed what the impact of
onor serostatus was in recipients who exhibited prior immu-
ity to CMV.
. MethodsThe patient cohort was taken from those individuals
ndergoing renal transplantation at the Churchill Hospi-
al, Oxford. Individuals were routinely tested for CMV
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Table 1
Patient characteristics and CMV antigenemia
D+R+ D−R+ D+R− D−R− Total
Patients 128 (26%) 107 (22%) 132 (27%) 119 (25%) 486
CMV detected 55 27 73 17 172 (35%)
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impact on overall infection outcome, even in a group where
about half the recipients were already seropositive.
Fig. 1. Comparison of CMV antigenemia rates in different clinical risk
groups. The upper panel (A) shows the proportion of individuals experi-
encing CMV antigenemia over the follow-up period in the four differentMV >5 29 12
MV >100 7 4
erostatus pretransplant using CMV latex assays (BD,
harmingen). Antigenemia levels were assessed regularly
ost-transplant up to 99 days, using a cytospin prepara-
ion of buffy coat cells from peripheral blood and direct
p65 analysis using APAAP immunochemistry (mouse
nti-HCMV pp65 (CLONAB)). The immunosuppressive reg-
men varied little over this period—all patients received
yclosporin A (dosage adjusted according to levels), methyl-
rednisolone and azathioprine conventional triple therapy.
MV seronegative donors received CMV negative blood
roducts. Prophylaxis for CMV infection (ganciclovir or aci-
lovir/valaciclovir) was not used during the period studied.
Seven hundred and thirty-five patients were transplanted
ver the study period. These were divided according to pre
ransplantation serostatus into four groups—D+R+ (30%),
+R− (23%), D−R+ (24%) and D−R− (23%). Full follow-
p data including details of the antigenemia testing up to 99
ays were available on 486 patients (Table 1) and it was this
roup that was analysed in detail.
Statistical analysis was performed using Graphpad Prism
oftware. Analysis of proportion was performed using
isher’s exact tests. To account for multiple comparisons, a
value of <0.05/8, i.e. <0.00625 has been used (Bonferroni
orrection).
. Results
Overall, 35% of patients experienced antigenemia dur-
ng the 99 day follow-up period, in about half of whom this
eached a level of over 5/50,000 cells in blood (Table 1).
smaller fraction reached very high levels of antigenemia,
lthough since this will be influenced by the treatment insti-
uted and the response to therapy, it was not analysed further.
Amongst those with antigenemia, the frequencies varied
idely between the four patient groups (Table 1 and Fig. 1).
he extremes were seen in the seronegative recipient group.
mongst these, those receiving a kidney from a seropositive
onor (D+R−) showed an antigenemia rate of 55%, while
hose receiving an organ from a seronegative donor had a
asal rate of 14% (D−R−).
For seropositive recipients, the overall infection rate was
3% in those receiving an organ from a seropositive donor
D+R+), compared to 25% if the donor was seronegative
D−R+). Similarly, for antigenemia levels >5/50,000, the
nfection rates were 29% and 12%, respectively. The latter
epresents an odds ratio of 2.9 (p = 0.002). While the greatest
c
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c40 8 89 (18%)
9 3 23 (4%)
ate of antigenemia >5/50,000 is seen in the D+R− group, the
dds ratio compared to D+R+ is not significant (OR = 1.65;
able 2).
Overall, the risk of infection in R− recipients was 35%,
ompared to 36% in the R+ group (p = n.s.). When anal-
sed by donor serostatus, D+ organs were associated with
49% infection rate in the recipients, compared to 19% in
− organs (p < 0.0001, OR = 4.0). Similarly, when assessing
he rate of infection >5/50,000, no significant difference was
een comparing R+ and R− groups (21% vs. 25%, p = n.s.),
hile D+ vs. D− groups showed a major effect (35% vs.
0%; p < 0.0001, OR = 4.9). Thus, donor status had a majorlinical groups. The lower panel (B) shows the frequency of antigenemia at
level >5/50,000 over the same period. The mean onset of antigenemia did
ot differ between the different groups. The p value refers to the impact of
onor serostatus in the seropositive recipient group. Other p values for these
omparisons are shown in Table 2.
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Table 2
Odds ratios for antigenemia (upper table) or antigenemia >5 (lower table)
Comparison (antigenemia ±) Odds ratio (OR) 95% confidence interval p value
D+R+ vs. D−R+ 2.2 1.28–3.91 0.006
D+R+ vs. D+R− 0.61 0.37–0.99 n.s. (0.049)
D+R+ vs. D−R− 4.52 2.43–8.42 <0.001
D+R− vs. D−R− 7.42 4.00–13.77 <0.001
D+R− vs. D−R+ 3.67 2.10–6.39 <0.001
D−R+ vs. D−R− 2.03 1.03–3.97 n.s (0.044)
D+ vs. D− 4.01 2.66–6.04 <0.001
R+ vs. R− 0.81 0.53–1.23 n.s. (0.33)
Comparison (antigenemia >5) Odds ratio (OR) 95% confidence interval p value
D+R+ vs. D−R+ 2.9 1.47–5.89 0.002
D+R+ vs. D+R− 0.61 0.36–1.01 n.s. (0.07)
D+R+ vs. D−R− 4.97 2.28–10.84 <0.001
D+R− vs. D−R− 8.2 3.82–17.60 <0.001
D+R− vs. D−R+ 4.85 2.47–9.54 <0.001
D−R+ vs. D−R− 1.69 0.69–4.13 n.s. (0.2)
D+ vs. D− 4.9 2.95–8.17 <0.001
R+ vs. R− 0.99 0.66–1.49 n.s. (1.0)
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sata are derived from Fig. 1 and Table 1. Fisher’s exact test was used to c
0.05/8, i.e. <0.00625 has been used (Bonferroni correction).
. Discussion
Much work in the past has identified CMV as a signif-
cant complication of renal transplantation, with additional
ong term consequences in terms of graft survival (Gjertson,
992, 2003; Hirata et al., 1996; Schnitzler et al., 2003). It
s clear that pre-existing immunity modifies the course of
nfection, as the most significant disease is seen in seroneg-
tive recipients who undergo primary infection. It is for this
eason that such individuals are often specifically targeted in
rophylactic regimens. Nevertheless a significant burden of
nfection lies outside this group.
The Oxford transplantation programme established at an
arly stage a regular screening protocol for identifying CMV
ntigenemia in the recipient cohort, regardless of donor and
ecipient serostatus. This gave us a valuable data resource
ith which to tackle the question of how recipient and donor
erostatus influence CMV infection/reactivation. Due to the
revalence of CMV in the UK, the proportions of individuals
n the four potential groups (D+R+, D+R−, D−R+, D−R−)
ere roughly equal, thus allowing reasonable comparisons
o be made in a large group of patients all undergoing similar
ell-established regimens of pre- and post-operative moni-
oring and care (Boeckh et al., 1994; Pancholi et al., 2004;
he et al., 1990).
This study suggests that donor serostatus plays a very
mportant role in the outcome of transplantation, and one
hich may be overlooked in the group of seropositive recip-
ents. Thus even in the R+ group the receipt of a D+ organ
ncreases the risk of CMV antigenemia by two- to threefold
ompared to receiving a D− organ. This is substantially less
han the relative excess risk in the R− group (seven to eight-
old), confirming that recipient serostatus also plays a major
ole, but raises the important issue of to what extent infection
r
t
c
istatistical significance. To account for multiple comparisons, a p value of
een in this period post-transplant is due to reactivation vs.
uperinfection.
In principle the D−R− group represents the background
nfection rate. Sources of error here might include false
egatives in D/R serostatus, but if these are truly both neg-
tive the infection may represent a nosocomial or indeed a
on-hospital source. The infection in the D−R+ group then
epresents, possibly on top of the background rate, the true
eactivation rate. The difference between the D+R+ group
nd the D−R+ group must represent the superinfection rate.
his is substantial, and furthermore the difference between
−R+ and D−R− (i.e. presumed reactivation) is by com-
arison small and statistically nonsignificant. This suggests
hat a large burden of disease seen in the R+ cohort is due to
uperinfection rather than reactivation.
One possible explanation is that pre-existing immunity is
elatively strain specific, and that the incoming strain is not
fficiently controlled by the combined cellular and humoral
esponses. There is some evidence for this idea in studies of
hildren born with congenital CMV (Boppana et al., 1999,
001; Fowler et al., 1992). Here sequence analysis has shown
hat a superinfecting strain present during pregnancy appears
o infect the fetus and cause disease, despite pre-existing anti-
ody (and presumably T cell immunity) in the mother. There
s little data on the diversity of strains infecting the transplant
opulation and the cross-protection between them, but this
ssue will of significance in future studies.
A second interesting possibility is that localisation of
irus in the incoming kidney may provide a niche for
uperinfection. This may be a difficult area for immune
esponses—since humoral immunity will not provide pro-
ection against an infected cell and cellular immunity may be
ompromised in this organ. The latter may result partly from
ts anatomy and/or the expression of Class I molecules in
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pithelial cells. HCMV can exist in replicative form in normal
idneys for extended periods in the face of very strong CD8+
nd CD4+ T cells (Griffiths, 1988), as can other pathogens
Ciurea et al., 1999). A further issue in transplant patients may
e matching of Class I molecules. HCMV specific CD8+ T
ell responses are robust but are focused on specific peptides.
f the restricting allele for such a response is not present in
he organ then this might further impair the capacity of a host
esponse to contain infection. We investigated the impact of
LA mismatching in this cohort; however, overall we found
o influence of the number of matches at Class I or Class II
oci on the rate of antigenemia in different D/R groups (data
ot shown).
Overall these data therefore provide a unique analy-
is of CMV infection in a large prospectively analysed
ohort. On the one hand an important clinical message is
hat donor serostatus should be considered an important
ariable in determining outcome even in seropositive recip-
ents, and potentially this group might also benefit in future
rom CMV prophylaxis in the same way as seronegative
ecipients—this issue is being addressed in a follow-up study
ince prophylaxis has been introduced. On the other hand the
mmunological and virological basis for this enhanced risk of
ntigenemia requires further analysis, including better data
n the diversity of and cross-reactivity between circulating
MV strains. Even with prophylaxis, CMV infection remains
n important threat to the transplant recipient and a better
nderstanding of the basis for it might provide new avenues
or protection in those at risk.
cknowledgements
We would like to thank the patients and staff at the Renal
nit, Churchill Hospital, Oxford, and Sue Fuggle and the staff
f Tissue Typing, Churchill Hospital, Oxford. PK is funded
y the Wellcome Trust.eferences
oeckh M, Myerson D, Bowden RA. Early detection and treatment of
cytomegalovirus infections in marrow transplant patients: methodologi-
T
Wl Virology 41 (2008) 92–95 95
cal aspects and implications for therapeutic interventions. Bone Marrow
Transplant 1994;14(Suppl. 4):S66–70.
oppana SB, Fowler KB, Britt WJ, Stagno S, Pass RF. Symptomatic
congenital cytomegalovirus infection in infants born to mothers with
preexisting immunity to cytomegalovirus. Pediatrics 1999;104:55–
60.
oppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine trans-
mission of cytomegalovirus to infants of women with preconceptional
immunity. N Engl J Med 2001;344:1366–71.
rayman KL, Dafoe DC, Smythe WR, Barker CF, Perloff LJ, Naji
A, et al. Prophylaxis of serious cytomegalovirus infection in renal
transplant candidates using live human cytomegalovirus vaccine.
Interim results of a randomized controlled trial. Arch Surg 1988;123:
1502–8.
iurea A, Klenerman P, Hunziker L, Horvath E, Odermatt B, Ochsen-
bein AF, et al. Persistence of lymphocytic choriomeningitis virus at
very low levels in immune mice. Proc Natl Acad Sci USA 1999;96:
11964–9.
owler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome
of congenital cytomegalovirus infection in relation to maternal antibody
status. N Engl J Med 1992;326:663–7.
jertson DW. Multifactorial analysis of renal transplants reported to the
United Network for Organ Sharing Registry. Clin Transpl 1992:299–
317.
jertson DW. Look-up survival tables for living-donor renal transplants:
OPTN/UNOS data 1995–2002. Clin Transpl 2003:337–86.
riffiths PD. Chronic cytomegalovirus infection. J Virol Methods
1988;21:79–86.
irata M, Terasaki PI, Cho YW. Cytomegalovirus antibody status and renal
transplantation: 1987–1994. Transplantation 1996;62:34–7.
ancholi P, Wu F, Della-Latta P. Rapid detection of cytomegalovirus
infection in transplant patients. Expert Rev Mol Diagn 2004;4:231–
42.
ao M, Finny GJ, Abraham P, Juneja R, Thomas PP, Jacob CK, et al.
Cytomegalovirus infection in a seroendemic renal transplant popula-
tion: a longitudinal study of virological markers. Nephron 2000;84:367–
73.
icart MJ, Malaise J, Moreno A, Crespo M, Fernandez-Cruz L.
Cytomegalovirus: occurrence, severity, and effect on graft survival in
simultaneous pancreas–kidney transplantation. Nephrol Dial Transplant
2005;20(Suppl. 2):ii25–32.
chnitzler MA, Lowell JA, Hardinger KL, Boxerman SB, Bailey TC,
Brennan DC. The association of cytomegalovirus sero-pairing with out-
comes and costs following cadaveric renal transplantation prior to the
introduction of oral ganciclovir CMV prophylaxis. Am J Transplant
2003;3:445–51.he TH, van der Bij W, van den Berg AP, van der Giessen M, Weits
J, Sprenger HG, et al. Cytomegalovirus antigenemia. Rev Infect Dis
1990;12(Suppl. 7):S734–44.
arrell MJ, Chinn I, Morris PJ, Tobin JO. The effects of viral infections on
renal transplants and their recipients. Q J Med 1980;49:219–31.
